About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
GRACE
cancergrace.org
Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
NSCLC Q&A: After CRT, What Is Recommended for 2L Treatment and Timing in Stage 3 ROS1+ Lung Cancer?
By
GRACE
FEATURING
Jessica Lin
,
Chul Kim
By
GRACE
FEATURING
Jessica Lin
,
Chul Kim
21 views
April 20, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
Featured Video
21:09
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
2021 Targeted Therapies Patient Forum
13:32
CancerGRACE
Targeted Therapies in Oligo-Metastatic NSCLC
Feat.
T. Leal
17:04
CancerGRACE
Genotype Directed Therapies: Their Role in Earlier Stage NSCLC
Feat.
Z. Piotrowska
15:19
GRACE
The Role of Chemotherapy in Driver Positive NSCLC
Feat.
J. Weiss
05:59
GRACE
Will There Ever be an Opportunity to Use TKI + IO Together in NSCLC?
Feat.
J. West,
Z. Piotrowska,
B. Levy
08:30
CancerGRACE
Is There a Role for Chemo + IO in NSCLC With EGFR Mutations and When…
Feat.
J. West,
Z. Piotrowska,
B. Levy
09:16
GRACE
Is There a Role for Single Agent Immunotherapy Ever in Driver Mutati…
Feat.
J. West,
Z. Piotrowska,
B. Levy
22:23
GRACE
Targeted Therapy for Rare NSCLC Drivers: NTRK, RET, and HER2
Feat.
M. Das
21:10
GRACE
Tissue Genotyping: Challenges and Best Practices - Optimal NGS Platf…
Feat.
J. Weiss
14:32
GRACE
Current Standards and Novel Therapies for Sensitizing Mutations in E…
Feat.
J. West
04:43
GRACE
Common Mutations Changing to Different Drivers: Should NSCLC Be Biop…
Feat.
J. West,
J. Gainor
20:47
GRACE
ALK Therapies in NSCLC: Which One Comes First and How Do We Sequence
Feat.
C. Kim
19:32
GRACE
ROS1 Therapies in NSCLC: Current and Emerging Treatment Options
Feat.
J. Lin
04:06
CancerGRACE
NSCLC Q&A: After CRT, What Is Recommended for 2L Treatment and T…
Feat.
J. Lin,
C. Kim
16:50
GRACE
KRAS Directed Therapies in NSCLC: A New Horizon
Feat.
L. Bazhenova
16:35
GRACE
Liquid Biopsies in NSCLC: Current Applications
Feat.
J. Thompson
